Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Business Wire•06/08/2026•16:01 ET
0
Whiz Insights
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Announced positive topline results from Phase 3 Emerge study of DT120 ODT in major depressive disorder (MDD), demonstrating rapid, robust, and durable efficacy
Get started
Create a free account to read the full story.